Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A

NANot yet recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

April 25, 2026

Study Completion Date

April 25, 2027

Conditions
Complex Regional Pain Syndromes
Interventions
DRUG

Botulinum toxin A

Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin type A 75 IU mixed with 3 ml of non-preserved saline solution are injected in the patients in the control and botulinum toxin groups, respectively.

All Listed Sponsors
lead

Seoul National University

OTHER

NCT06470581 - Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A | Biotech Hunter | Biotech Hunter